'ne Dosis Wissen | Der Medizin-Podcast für Menschen im Gesundheitswesen · Apotheken Umschau Pro & gesundheit-hören

Automatisierte Beatmung bei extrem Frühgeborenen

April 9, 2026·9 min

The episode opens by outlining the critical challenge of oxygen management for extremely preterm infants, who often require weeks of respiratory support. Both too little oxygen (hypoxia) and too much (hyperoxia) can cause serious harm, damaging organs like the brain, lungs, and eyes. The hosts introduce a recent study published in The Lancet Child & Adolescent Health in March 2026, led by researchers from Tübingen and Mainz. They reference an interview with neonatology expert Ursula Felderhoff-Müser from Essen University Hospital. The episode details the physiology: hyperoxia triggers inflammation in immature organs, while hypoxia leads to cell death and developmental delays. It explains that preterm infants have irregular breathing, causing fluctuating oxygen levels that nurses must manually adjust, a labor-intensive task. The proposed solution is automated 'Closed Loop Control' systems. The discussed study was a multicenter, randomized controlled trial across over 30 neonatal ICUs in Germany, the Netherlands, the UK, and China. It aimed to enroll 2,340 infants but included 1,082. The primary outcome combined death, necrotizing enterocolitis, bronchopulmonary dysplasia, or severe retinopathy. Results showed the combined endpoint occurred in 39% of the automated-plus-manual group and 41% of the manual-only group, a non-significant difference. Individual outcomes like mortality were also similar. The study concluded automated control was feasible and safe but did not improve short-term clinical outcomes. Expert analysis highlights that while not clinically superior, these systems could reduce the workload of frequent oxygen adjustments and alarm fatigue for nurses. This is framed as valuable given severe staffing shortages in pediatric nursing. The episode notes study limitations, including not reaching the target sample size and potential bias from the open-label design. It concludes by suggesting future research should repeat the study in countries like the US, where baseline complication risks are much higher, potentially making benefits more detectable.

Listen to the show on

Apple Podcasts Spotify